- Home
- IMCC vs IMNN Comparison
IMCC vs IMNN Comparison
Compare IMCC & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- IMNN
- Stock Information
- Founded
- IMCC 1980
- IMNN 1982
- Country
- IMCC Israel
- IMNN United States
- Employees
- IMCC N/A
- IMNN N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- IMNN Health Care
- Exchange
- IMCC Nasdaq
- IMNN Nasdaq
- Market Cap
- IMCC 11.8M
- IMNN 12.1M
- IPO Year
- IMCC N/A
- IMNN 1985
- Fundamental
- Price
- IMCC $2.81
- IMNN $7.00
- Analyst Decision
- IMCC
- IMNN Buy
- Analyst Count
- IMCC 0
- IMNN 2
- Target Price
- IMCC N/A
- IMNN $210.00
- AVG Volume (30 Days)
- IMCC 75.2K
- IMNN 285.4K
- Earning Date
- IMCC 08-13-2025
- IMNN 08-13-2025
- Dividend Yield
- IMCC N/A
- IMNN N/A
- EPS Growth
- IMCC N/A
- IMNN N/A
- EPS
- IMCC N/A
- IMNN N/A
- Revenue
- IMCC $37,894,737.00
- IMNN N/A
- Revenue This Year
- IMCC $47.12
- IMNN N/A
- Revenue Next Year
- IMCC $12.83
- IMNN N/A
- P/E Ratio
- IMCC N/A
- IMNN N/A
- Revenue Growth
- IMCC 12.68
- IMNN N/A
- 52 Week Low
- IMCC $1.29
- IMNN $5.55
- 52 Week High
- IMCC $7.12
- IMNN $54.75
- Technical
- Relative Strength Index (RSI)
- IMCC 46.59
- IMNN 35.49
- Support Level
- IMCC $2.90
- IMNN $7.46
- Resistance Level
- IMCC $3.21
- IMNN $9.35
- Average True Range (ATR)
- IMCC 0.34
- IMNN 1.23
- MACD
- IMCC -0.07
- IMNN 0.08
- Stochastic Oscillator
- IMCC 5.05
- IMNN 9.00
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).